|Bid||7.34 x 800|
|Ask||7.35 x 1000|
|Day's Range||7.13 - 7.49|
|52 Week Range||4.68 - 19.22|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 13, 2022 - Apr 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Oct 14, 1999|
|1y Target Est||3.00|
Why Rite Aid's (NYSE: RAD) stock pop and raised guidance still aren't enough to get him interested in buying shares. Additionally, with shares down nearly 70% over the past year, is Zoom Video Communications (NASDAQ: ZM) a screaming buy or past its prime? To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
Yahoo Finance Live anchors discuss third-quarter earnings for Walgreens.
PHILADELPHIA, June 30, 2022--Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD), announced the launch of a specialty generic medication enhancement to its managed copay solutions effective June 1, 2022. The enhancement allows members to receive generic versions of certain specialty medications at a $0 copay and has the potential to provide an average savings of up to $40,000 annually.